Healthcare
OraSure Technologies, Inc.(OSUR)
Live Price
Offline$4.31
-3.69% today
1Y Change
+55.75%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $200.00M
- Revenue Growth
- -38.1%
- EPS Growth
- -261.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
OraSure Technologies, Inc. (OSUR) is a Healthcare stock with a market cap of $200.00M and listed on NASDAQ. The stock last traded around $4.30 and up 55.7% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -38.1%, EPS growth of -261.5%, a dividend yield of 0.0%. What stands out right now is revenue -38.1%, EPS -261.5%, free cash flow -100.2% with operating margin -59.2% and ROIC -18.6%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OSUR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-38.1% vs +7.6% peer median
Operating Margin
Below sector median
-59.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -38.1% and EPS is at -261.5%, with operating margin around -59.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +4.3% | +1.3% | +39.0% |
2026 Feb 25, 2026 | -11.8% | +10.0% | +7.5% | +12.1% |
2025 Nov 5, 2025 | +18.8% | -6.6% | -3.9% | +0.0% |
Benchmark Edge
OSUR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OSUR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OSUR Max Drawdown
-39.37%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OSUR and SPY.
Company Overview
OraSure Technologies, Inc.
NASDAQ Global Select
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
- Leadership
- Carrie Eglinton Manner
- IPO Date
- Nov 17, 1986
- Employees
- 501
- Street Address
- 220 East First Street
- Mailing
- Bethlehem, PA, 18015
- Region
- Bethlehem, PA, US
- Reporting Currency
- USD
- Investor Line
- 610 882 1820
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.8
- Price/Book
- 0.6
Growth
- Revenue
- -38.1%
- EPS
- -261.5%
- Free Cash Flow
- -100.2%
Profitability
- Gross Margin
- 38.2%
- Operating Margin
- -59.2%
- Net Margin
- -59.8%
- ROE
- -18.6%
- ROIC
- -18.6%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 6.58
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.